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This cross-sectional study was approved by the institutional re-
view committee and the subjects gave informed consent. Criteria
for inclusion were the diagnosis of Chagas disease determined by
positive serology, clinical, electrocardiographic or echocardiograph-
ic ﬁndings compatible with CHD, and sedentary lifestyle. Exclusion
criteria were the presence of systemic or heart disease by any other
causes, associated co-morbidities and the inability to perform the ex-
ercise tests.
The overall study population comprised patients with dilated leftThe Cardiopulmonary Exercise Testing (CPET) is considered the gold
standard in the assessment of functional capacity (FC). Peak oxygen up-
take (VO2peak) and the minute ventilation/carbon dioxide production
slope (VE/VCO2 slope) are the two most frequently assessed CPET vari-
ables in heart failure (HF) patients [1]. However, the test is expensive,
which limits its applicability in clinical routine and the Six-minute
Walk Test (6MWT) [2] may be an alternative approach. The effective-
ness of the 6MWT is well established in overall HF patients and the dis-
tance walked showed a moderate to strong correlation with VO2peak
evaluated by CPET [3].
Chagas heart disease (CHD) represents an important cause of HF,
with signiﬁcant socioeconomic impact, worse prognosis compared to
other cardiomyopathies and presents with some pathogenetic and clin-
ical peculiarities [4]. In CHD patients, the 6MWT distance correlated
with quality of life scores [5], hemodynamic and inﬂammatorymarkers
[6] and improvements in the heart rate variability after aerobic training
[7]. However, there are no available studies concerning CHD patients
that veriﬁed the association between the distance walked during the
6MWTwith CPET variables. Therefore, this studywas designed to assess
the correlation between the 6MWT distance and CPET variables in a/407, Centro, 30.180-100, Belo
osta).
.wide spectrum of CHD, and also to determine an optimal cutoff value
of 6MWT distance to identify functional impairment.
ventricle with impaired ventricular systolic function (dilated group)
and patients with normal left ventricular dimensions and function
(non-dilated group). The CPET was performed on a treadmill ramp pro-
tocol and the 6MWT was guided by current guidelines [2].
Chi-square, Mann–Whitney or independent t-test, as appropriate,
and Pearson correlation test were performed for data analysis, with sig-
niﬁcance levels at 0.001% and 0.05%. A receiver–operator curvewas con-
structed to determine the cutoff value of the 6MWT distance in the
overall populationwith the best combination of sensitivity and speciﬁc-
ity to identify functional impairment, deﬁned as VO2peak values below
20 mL·kg·min according to Webber classiﬁcation [8].
Forty-one CHD patients (47.8 ± 8.3 years, 28 males) were evalu-
ated. In the overall study population, the 6MWT distance correlated
with VO2peak (r = 0.586; p b 0.001) but not with VE/VCO2 slope
(r=−0.046; p= 0.776). Echocardiography parameters, 6MWT dis-
tance and CPET variables of the sample stratiﬁed according to left
ventricular systolic function are presented in Table 1.
The 6MWT distance correlated with VO2peak in both dilated
(n = 20) and non-dilated group (n = 21) (r = 0.612; p = 0.005
and r = 0.463; p = 0.035, respectively) (Fig. 1). No correlation
was found between the distance walked and the VE/VCO2 slope in
the dilated group (r =−0.322; p = 0.166) and in the non-dilated
group (r = −0.104; p = 0.662).
The area under the ROC curve to identify a VO2peak of, at least,
20 mL·kg·min by 6MWT distance was 0.765 (CI 95%: 0.596–0.933)
(Fig. 2). The optimal cut point value to identify functional impairment
was a distance less than 522 m, with sensitivity and speciﬁcity of
72.4% and 81.8%, respectively.
Table 1
Characteristics of the CHD patients stratiﬁed according to left ventricular systolic function.
Variables Dilated group
(n = 20)
Non-dilated group
(n = 21)
p value
LVEF (%) 38.00 (32.25–41.00) 63.00 (60.00–67.75) 0.001
LVDd (mm) 66.50 (61.00–71.25) 48.00 (44.50–52.00) 0.001
NYHA (n) I (5); II (10); III (5) I (16); II (4); III (1) 0.004
6MWT distance (m) 508.25 ± 82.41 571.24 ± 73.36 0.045
VO2peak (mL·kg·min) 21.92 ± 6.16 29.83 ± 7.29 0.001
VE/VCO2 slope 33.62 ± 5.65 30.26 ± 3.67 0.029
%HR predicted (%) 78.00 ± 13.87 87.89 ± 10.08 0.020
Data presented as mean and standard deviation (mean ± SD), median (MD) and inter-
quartile range (25–75%) or absolute number. p value is the difference between dilated
and non-dilated group and the values highlighted in bold are statistically signiﬁcant
(p b 0.05). LVEF = left ventricular ejection fraction, LVDd = left ventricular end-diastolic
diameter, NYHA = New York Heart Association, 6MWT distance = distance walked in
Six-minute Walk Test, VO2peak = peak oxygen uptake, VE/VCO2 slope = minute ventila-
tion/carbon dioxide production slope, and %HR predicted = percentage ofmaximal heart
rate predicted achieved in the effort.
662 H.S. Costa et al. / International Journal of Cardiology 177 (2014) 661–663To the best of our knowledge, this is the ﬁrst study that demonstrat-
ed the association between the 6MWT distance and CPET variables in
CHDpatients. The followingmain ﬁndings are: (1) the signiﬁcant corre-
lation between the 6MWTdistance and VO2peak in CHDpatients, (2) theFig. 1. Correlation between the distance walked in 6MWT and peak oxygen uptake (peak
VO2) (A) in the dilated group and (B) in the non-dilated group.
Fig. 2.Receiver-operating characteristic (ROC) curve representing the accuracy of distance
walked in 6MWT to identify a VO2peak of, at least, 20 mL·kg·min.stronger correlation between 6MWT distance and VO2peak in CHD pa-
tients with impairment of ventricular function than those with pre-
served systolic function and (3) the 6MWT distance of 522 m is the
optimal cutoff value to identify patients with functional impairment.
These results have important clinical meaning in the setting of Chagas
disease, since endemic areas are generally poor, have few resources
and the maximal exercise test may not be available.
Aiming to verify the correlation between the 6MWT distance and
VO2peak in HF patients, a recent systematic review [3] showed that
most of the analyzed studies found amoderate to strong correlation be-
tween these variables. The moderate correlation found in the present
study between the distancewalked andVO2peak conﬁrms the usefulness
of the 6MWT in the evaluation of FC in HF patients regardless of etiolo-
gy. Additionally, our results suggest that the 6MWT is better usedwhen
evaluating FC of patients with more severely impaired ventricular func-
tion.We hypothesized that the 6MWTmethodology can underestimate
the FC of patients with better systolic function. At 6MWT, patients are
instructed to walk as fast as possible but without running [2] and it
can be a limiting factor in the evaluation of patients with preserved sys-
tolic function, generally with higher FC. This fact does not occur during
the CPET, which is amaximal test and the patient is encouraged to run if
possible.
Recently, a previous study reported that the VE/VCO2 slope was the
only variable assessed by CPET considered an independent predictor of
survival in CHD patients [9]. The present study found no correlation be-
tween this variable and the 6MWT distance but, unlike the VO2peak, the
VE/VCO2 slope is more related to the central function than to patient ef-
fort [10], which possibly explains the lack of correlation between these
variables.
We also demonstrated that the 6MWT distance has good sensitivity
and speciﬁcity in identifyingpatientswith functional impairment. Other
authors [11] have shown the effectiveness of the 6MWT in screeningpa-
tients whowere referred for heart transplantationwith good sensitivity
(80%) and speciﬁcity (83%). Thus, the 6MWT appears to be a simple, in-
expensive and useful test for risk stratiﬁcation based on functional im-
pairment in the overall HF patients and also due to CHD.
In conclusion, the 6MWT appears to be an alternative tool in the
assessment of FC in CHD patients and can also identify patients who
have functional impairment with impact on the management of these
patients.
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